INM (InMed) חוב לטווח ארוך

InMed Pharmaceuticals (INM) is developing synthetic cannabinoids for the treatment of epidermolysis bullosa, although there are currently no actual patients. This price chart, coupled with long-term debt amounting to 0.00, highlights a capital deficit and stringent FDA oversight. The project relies on proprietary biosynthesis methods, creating a closed scientific environment for the licensing of technologies to B2B partners in the field of dermatology.

The indicator is calculated as the share of debt capital with a maturity of more than one year within the overall business financing structure. This metric identifies a systemic imbalance between long-term liabilities and equity, signaling risks of share devaluation. For InMed Pharmaceuticals (INM), the credit burden is typically limited to laboratory maintenance costs and standard waste disposal. Analyzing the issuer's long-term liabilities chart on GURU.Markets allows for the timely detection of a dangerous accumulation of debt. Monitoring this indicator protects the investor from a catastrophic drawdown of capital.